priors.science/reviews/psoriasis-psoriatic-arthritis

Psoriasis Psoriatic Arthritis

The current evidence on 27 claims, ordered from most established to most contested. Each score is the panel’s evidence certainty — how firmly the literature supports the claim as stated.

27claims tracked
210primary papers reviewed
5 Jun 2026latest evidence review
Weeklyre-scored against new papers
11 Established · 10 Likely · 6 Uncertain · 0 Doubtful  |  four-reviewer panel · PICO Framework
SignalClaimStandingEvidence certaintyCorpus
StableBimekizumab versus secukinumab PASI 90Pso Il17Established88%10
StableIL-17 inhibitors versus ustekinumab PASI 90Pso Il17Established88%9
StableIxekizumab PASI 100 response ratesPso Il17Established87%10
StableRisankizumab versus ustekinumab PASI 90Pso Il23Established87%10
StableDeucravacitinib versus apremilast PASI 75Pso SMEstablished87%9
StableApremilast PASI 75 efficacyPso SMEstablished86%9
StablePsoriasis as independent cardiovascular risk factorPsa CVDEstablished85%8
StableSecukinumab pooled PASI 90 responsePso Il17Established85%10
StableUpadacitinib ACR50 versus placebo in TNF-inhibitor inadequate respondersPsa JAKEstablished85%8
StableTofacitinib ACR20 in psoriatic arthritisPsa JAKEstablished85%8
StableTofacitinib major adverse cardiovascular events versus TNF inhibitors in rheumatoid arthritisPsa JsafEstablished85%8
StableGuselkumab 2-year PASI 90 durabilityPso Il23Likely81%9
StableGuselkumab ACR20 in biologic-naive psoriatic arthritisPsa PJTLikely81%8
StableSecukinumab ASAS20 in axial psoriatic arthritisPsa AxlLikely80%8
StableRisankizumab minimal disease activity in psoriatic arthritisPsa PJTLikely80%8
StableBimekizumab ACR50 in biologic-naive psoriatic arthritisPsa PJTLikely80%8
StableUpadacitinib versus adalimumab in biologic-naive psoriatic arthritisPsa JAKLikely79%8
StableSecukinumab 5-year ACR20 durabilityPsa PJTLikely78%9
StableBiologics reduce psoriasis cardiovascular disease riskPsa CVDLikely71%8
StableTreat-to-target improves psoriatic arthritis outcomesPsa BMKLikely70%8
StableIL-17 inhibitors associated with inflammatory bowel disease incidencePsa CVDLikely70%8
StableIxekizumab versus adalimumab ACR50 in psoriatic arthritisPsa PJTUncertain60%9
StableHLA-Cw6 predicts ustekinumab responsePsa BMKUncertain55%8
StableJAK inhibitors venous thromboembolism riskPsa JsafUncertain55%8
StableIL-23p19 inhibitors post-withdrawal durabilityPso Il23Uncertain48%8
StableIL-17 inhibitors: axial psoriatic arthritis versus axial spondyloarthritis responsePsa AxlUncertain46%8
StableJAK cardiovascular risk signal extends to psoriatic arthritisPsa JsafUncertain42%8
Standing — what the evidence certainty means
Established≥ 85%Strong, consistent evidence. Unlikely to change.
Likely65–84%Well supported, with some gaps or indirect evidence.
Uncertain40–64%Mixed or limited evidence. Genuinely open.
Doubtful15–39%Little support; the weight of evidence leans against it.
Refuted< 15%The evidence contradicts it — confidently false as stated.
Recent signal
strengthenedNew evidence raised the certainty since the last review.
weakenedNew evidence lowered the certainty since the last review.
newA claim added to the review recently.
StableNo recent change to the standing.
Standing, evidence certainty and corpus are always shown. The study behind each move, why it moved, and the sceptic’s challenge are delivered to subscribers.
Update your priors.Track this topic